Anti-PD-1 Therapy Enhances the Efficacy of CD30-Directed Chimeric Antigen Receptor T Cell Therapy in Patients With Relapsed/Refractory CD30+ Lymphoma

Anti-CD30 CAR-T is a potent candidate therapy for relapsed/refractory (r/r) CD30+ lymphomas with therapy limitations, and the efficacy needed to be further improved. Herein a multi-center phase II clinical trial (NCT03196830) of anti-CD30 CAR-T treatment combined with PD-1 inhibitor in r/r CD30+ lym...

Descripción completa

Detalles Bibliográficos
Autores principales: Sang, Wei, Wang, Xiangmin, Geng, Hongzhi, Li, Tianci, Li, Dashan, Zhang, Bingpei, Zhou, Yi, Song, Xuguang, Sun, Cai, Yan, Dongmei, Li, Depeng, Li, Zhenyu, Li, Caixia, Xu, Kailin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9010867/
https://www.ncbi.nlm.nih.gov/pubmed/35432352
http://dx.doi.org/10.3389/fimmu.2022.858021

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9010867/
https://www.ncbi.nlm.nih.gov/pubmed/35432352
http://dx.doi.org/10.3389/fimmu.2022.858021

Ejemplares similares